Aurinia Pharmaceuticals

1D
1W
1M
3M
YTD
1Y
5Y
ALL

Why Robinhood?

Robinhood gives you the tools you need to put your money in motion. You can buy or sell AUPH and other ETFs, options, and stocks.

About AUPH

Aurinia Pharmaceuticals, Inc. is a clinical stage bio-pharmaceutical company, which engages in the research, development, and commercialization of therapeutic drugs. The company was founded by Robert Foster, Richard Glickman, and Michael Martin on June 16, 1993 and is headquartered in Edmonton, Canada. 

CEO
Peter S. Greenleaf
CEOPeter S. Greenleaf
Employees
128
Employees128
Headquarters
Edmonton, Alberta
HeadquartersEdmonton, Alberta
Founded
1993
Founded1993
Employees
128
Employees128

AUPH Key Statistics

Market cap
1.97B
Market cap1.97B
Price-Earnings ratio
7.15
Price-Earnings ratio7.15
Dividend yield
Dividend yield
Average volume
1.38M
Average volume1.38M
High today
$14.82
High today$14.82
Low today
$14.46
Low today$14.46
Open price
$14.70
Open price$14.70
Volume
388.63K
Volume388.63K
52 Week high
$16.54
52 Week high$16.54
52 Week low
$6.83
52 Week low$6.83

Stock Snapshot

As of today, Aurinia Pharmaceuticals(AUPH) shares are valued at $14.80. The company's market cap stands at 1.97B, with a P/E ratio of 7.15.

On 2026-03-11, Aurinia Pharmaceuticals(AUPH) stock traded between a low of $14.46 and a high of $14.82. Shares are currently priced at $14.80, which is +2.3% above the low and -0.2% below the high.

The Aurinia Pharmaceuticals(AUPH)'s current trading volume is 388.63K, compared to an average daily volume of 1.38M.

During the past year, Aurinia Pharmaceuticals(AUPH) stock moved between $6.83 at its lowest and $16.54 at its peak.

During the past year, Aurinia Pharmaceuticals(AUPH) stock moved between $6.83 at its lowest and $16.54 at its peak.

AUPH News

Simply Wall St 20h
A Look At Aurinia Pharmaceuticals Valuation After Strong Growth And Optimistic 2026 Guidance

Aurinia Pharmaceuticals (AUPH) just paired a strong 2025 earnings release with fresh 2026 guidance, outlining expectations for total revenue of US$315 million t...

A Look At Aurinia Pharmaceuticals Valuation After Strong Growth And Optimistic 2026 Guidance
Simply Wall St 4d
Aurinia Pharmaceuticals Earnings Strength And Valuation Gap Attract Investor Attention

Aurinia Pharmaceuticals reported four consecutive quarters of positive earnings surprises alongside improved profitability. Recent updates highlight strong sal...

Aurinia Pharmaceuticals Earnings Strength And Valuation Gap Attract Investor Attention
TipRanks 6d
Aurinia Pharmaceuticals Earnings Call Highlights Growth And Risks

Aurinia Pharmaceuticals ((AUPH)) has held its Q4 earnings call. Read on for the main highlights of the call. Claim 70% Off TipRanks Premium Unlock hedge fund-le...

Analyst ratings

57%

of 7 ratings
Buy
57.1%
Hold
42.9%
Sell
0%

People also own

Based on the portfolios of people who own AUPH. This list is generated using Robinhood data, and it’s not a recommendation.

Similar Marketcap

This list is generated by looking at the six larger and six smaller companies by market cap in relation to this company.

Popular Stocks

This list is generated by looking at the top 100 stocks and ETFs most commonly held by Robinhood customers and showing a random subset

Newly Listed

This list is generated by showing companies that recently went public.

All investments involve risks, including the loss of principal. Securities trading offered through Robinhood Financial LLC, Member SIPC and a registered broker-dealer. Options are risky and aren’t suitable for all investors. To learn more about risks, read the Options Disclosure Document.